CX 295

Drug Profile

CX 295

Alternative Names: AK 295; Vasolex

Latest Information Update: 13 Aug 1999

Price : $50

At a glance

  • Originator Cortex Pharmaceuticals
  • Class Anti-ischaemics; Neuroprotectants
  • Mechanism of Action Calpain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cerebral vasospasm; CNS trauma; Stroke

Most Recent Events

  • 13 Aug 1999 Discontinued-Preclinical for Cerebral vasospasm in USA (Unknown route)
  • 13 Aug 1999 Discontinued-Preclinical for CNS trauma in USA (Unknown route)
  • 13 Aug 1999 Discontinued-Preclinical for Stroke in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top